Done deal: The Tipline for 22 November 2019

Bristol-Myers Squibb has completed its $74 billion takeover of biotechnology company Celgene. The companies announced the deal in January and last week received conditional approval with a narrow 3-2 vote from the Federal Trade Commission. The companies agreed to the largest divestiture in US merger control history – Celgene’s sale of psoriasis drug Otezla to Amgen for $13.4 billion – to obtain FTC clearance.

Unlock unlimited access to all Global Competition Review content